This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 Mar 2014

Succinity Produces First Commercial Quantities of Bio-Based Succinic Acid

Succinity GmbH, the joint venture between Corbion Purac and BASF for the production and commercialization of bio-based succinic acid, has announced the successful start-up of its first commercial production facility. The plant, located at the Corbion Purac site in Montmeló, Spain, has an annual capacity of 10,000 metric tons and is producing commercial quantities of bio-based succinic acid for the global market. In addition to this first facility, Succinity plans a second large-scale facility. The final investment decision for this facility will be made following a successful market introduction.

 

“The start-up of our first facility for Succinity bio-based succinic acid represents a key milestone in our plan to become a major producer of biobased succinic acid in the future,” comments Philipp Walter, Managing Director of Succinity. “The combined experiences of the team in Montmeló and the support from Corbion Purac and BASF have ensured the achievement of this important milestone within schedule. With the facility in Spain we will be able to serve the growing succinic acid market.”

 

The Succinity process is based on renewable raw materials and fixes carbon dioxide. The proprietary micro-organism Basfia succiniciproducens allows for a flexible usage of different feedstocks. Furthermore, Succinity bio-based succinic acid can be produced efficiently without major waste streams thanks to a closed-loop process. An elaborate downstream processing method ensures the production of high quality biobased succinic acid.

 

Based on technological advances and an increased need for renewable intermediates in different application fields, BASF and Corbion Purac have been working on the development of bio-based succinic acid since 2009. Bio-based succinic acid features a significantly improved carbon footprint compared to conventional, fossil-based succinic acid or other dicarboxylic acids. Bio-based succinic acid is a versatile building block with a significant market potential in the chemical intermediates market. It can be used in a variety of potential applications, such as bio-polymers (e.g. Polybutylene succinate, PBS), polyurethanes, coatings and life science products.
 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.